A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2(+) metastatic breast cancer.
文献类型:会议论文
作者 | Xu, Binghe; Ma, Fei; Chen, Shanshan; Li, Qiao; Yang, Fan; Zhang, Yifan; Chen, Xiaoyan; Zhong, Dafang; Zhang, Ge |
出版日期 | 2015-05-20 |
卷号 | 33 |
期号 | 15 |
会议录 | JOURNAL OF CLINICAL ONCOLOGY |
会议录出版者 | AMER SOC CLINICAL ONCOLOGY |
文献子类 | Meeting Abstract |
语种 | 英语 |
WOS研究方向 | Oncology |
WOS记录号 | WOS:000358036902212 |
源URL | [http://119.78.100.183/handle/2S10ELR8/266128] |
专题 | 中国科学院上海药物研究所 |
作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China 2.Jiangsu Hengrui Med Co LTD, Shanghai, Peoples R China 3.Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China |
推荐引用方式 GB/T 7714 | Xu, Binghe,Ma, Fei,Chen, Shanshan,et al. A phase I study for tolerability, safety, and pharmacokinetics of pyrotinib, a novel irreversible HER2 and EGFR inhibitor, in Chinese patients with HER2(+) metastatic breast cancer.[C]. 见:. |
入库方式: OAI收割
来源:上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。